[] According to Muller et al (2023), animal studies reveal that GLP-1 like exenatide and liraglutide are associated with reduced fetal growth, delayed skeletal ossification, and skeletal anomalies, primarily in species such as rats and rabbits
Root cause of most GLP-1 problems in India: not the drug alone When you look carefully, most GLP-1 horror stories in India trace back to a few root causes: Wrong choice of patient (very low BMI, eating disorders, high-risk medical history) Buying and using drugs without a proper prescription or follow-up Rapid dose escalation to chase quick weight loss Not adjusting older diabetes medicines like sulfonylureas and insulin No guidance on diet, hydration, and muscle protection Fixing these root issues can sharply reduce GLP-1 side effects and make these medicines a safer, more useful ally in Indias diabetes and obesity epidemic
While Retatrutide remains investigational, eligible patients may be able to access medical weight loss options that are currently available through provider-supervised programs
Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes
A new peer-reviewed in vitro study using the standardized INFOGEST digestion model revealed Pepzyme AG promotes enhanced collagen breakdown and increased release of low-molecular-weight bioactive peptides, helping consumers utilize collagen more efficiently
